AR098436A1 - Compuestos tricíclicos de piperidina - Google Patents

Compuestos tricíclicos de piperidina

Info

Publication number
AR098436A1
AR098436A1 ARP140104303A ARP140104303A AR098436A1 AR 098436 A1 AR098436 A1 AR 098436A1 AR P140104303 A ARP140104303 A AR P140104303A AR P140104303 A ARP140104303 A AR P140104303A AR 098436 A1 AR098436 A1 AR 098436A1
Authority
AR
Argentina
Prior art keywords
alkyl
ring
alkoxy
heteroaryl
independently represent
Prior art date
Application number
ARP140104303A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR098436A1 publication Critical patent/AR098436A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente se refiere a su preparación, a sus sales farmacéuticamente aceptables, y a su utilización como productos farmacéuticos y a composiciones farmacéuticas. También a sus métodos de preparación, y especialmente a su utilización como moduladores de TPH (enzima implicada en la síntesis del neurotransmisor serotonina). Útiles en el tratamiento de trastornos o enfermedades pulmonares, osteoporosis, diabetes tipo 1, tipo 2, etc.. Reivindicación 1: Un compuesto de fórmula (1) donde X representa CH, o N; R representa hidrógeno, alquilo C₁₋₄, cicloalquilo C₃₋₆, o trifluoroalquilo C₁₋₃; R¹ᵃ y R¹ᵇ representan independientemente hidrógeno, metilo, etilo; o R¹ᵃ y R¹ᵇ junto con el átomo de carbono al cual están unidos para formar un anillo ciclopropilo; R² representa arilo o heteroarilo, donde dicho arilo o heteroarilo está independientemente sin sustituir, o sustituido una, dos o tres veces, donde los sustituyentes se seleccionan independientemente entre: alquilo C₁₋₄; alcoxi C₁₋₄; cicloalquilo C₃₋₆, que contiene opcionalmente uno o dos átomos de oxígeno en el anillo; fluoroalquilo C₁₋₃; fluoroalcoxi C₁₋₃; halógeno; ciano; -(CH₂)ₙ-NR²¹R²², donde n representa el número entero 0 ó 1; y R²¹ y R²² representan independientemente hidrógeno o alquilo C₁₋₃; o R²¹ y R²² junto con el átomo de nitrógeno al cual están unidos para formar un anillo saturado de 4 a 7 miembros, donde dicho anillo contiene opcionalmente un átomo de oxigeno en el anillo, y donde dicho anillo es opcionalmente sustituido con uno o dos sustituyentes flúor; carboxi; -CO-NR²³R²⁴, donde R²³ y R²⁴ representan independientemente hidrógeno o alquilo C₁₋₄; -CO-alcoxi C₁₋₄; -NR²⁵-CO-R²⁶, donde R²⁵ representa hidrógeno o alquilo C₁₋₄; y R²⁶ representa alquilo C₁₋₄ o un grupo -NR²⁷R²⁸ donde R²⁷ y R²⁸ representan independientemente hidrógeno o alquilo C₁₋₄; hidroxi-alquilo C₁₋₄; alcoxi C₁₋₃-alquilo C₁₋₄; hidroxi-alcoxi C₂₋₄; alcoxi C₁₋₃-alcoxi C₂₋₄; fenilo; heteroarilo de 5 miembros; o 3-metoxi-oxetan-3-ilo; R³ representa arilo o heteroarilo, donde dicho arilo o heteroarilo está independientemente sin sustituir, o sustituido una, dos, tres o cuatro veces, donde los sustituyentes se seleccionan independientemente entre: -NR⁴-SO₂-Y-R⁵, donde R⁴ representa hidrógeno o alquilo C₁₋₃; Y representa un enlace directo; y R⁵ representa alquilo C₁₋₄, o cicloalquilo C₃₋₆; o R⁴ representa hidrógeno o alquilo C₁₋₃; Y representa -NRY- donde RY representa hidrógeno o alquilo C₁₋₃; y R⁵ representa alquilo C₁₋₄; o R⁴ y R⁵ junto con el nitrógeno y el grupo -SO₂-Y-al cual están unidos para formar un anillo de 5, 6, ó 7 miembros, donde Y representa un enlace directo o -NRY- donde RY representa alquilo C₁₋₃; -CO-NR⁶R⁷, donde R⁶ y R⁷ representa independientemente hidrógeno, alquilo C₁₋₄, o cicloalquilo C₃₋₆; o R⁶ representa hidrógeno y R⁷ representa hidroxi, metoxi, o ciano; -SO₂-R⁸ donde R⁸ representa alquilo C₁₋₅, -alquilen C₂₋₄-CO-alcoxi C₁₋₃, o -NR⁸¹R⁸², donde R⁸¹ y R⁸² representan independientemente hidrógeno o alquilo C₁₋₄; alquilo C₁₋₄; alcoxi C₁₋₄; fluoroalquilo C₁₋₃; fluoroalcoxi C₁₋₃; cicloalquilo C₃₋₆ opcionalmente sustituido una vez con dimetilamino; halógeno; ciano; alcoxi C₁₋₃-alquilo C₁₋₄; alcoxi C₁₋₃-alcoxi C₂₋₄; -CO-alcoxi C₁₋₄; heteroarilo de 5 miembros; -(CH₂)ₘ-NR⁹R¹⁰; donde m representa el número entero 0 ó 1; y R⁹ y R¹⁰ representan independientemente hidrógeno, alquilo C₁₋₄, fluoroalquilo C₂₋₃, hidroxi-alquilo C₂₋₄, o alcoxi C₁₋₄-alquilo C₂₋₄; o R⁹ y R¹⁰ junto con el nitrógeno al cual están unidos para formar un anillo monocíclico de 4 a 7 miembros saturado o un sistema anular puenteado o fusionado bicíclico de 7 u 8 miembros saturado; donde independientemente dicho anillo o sistema anular contiene opcionalmente un átomo en el anillo de oxígeno o un grupo -NR¹¹- donde R¹¹ representa alquilo C₁₋₄; y donde dicho anillo o sistema anular es independiente y opcionalmente sustituido con: uno o dos sustituyentes flúor; o uno o dos sustituyentes metilo; o un sustituyente oxo unido a un átomo de carbono del anillo en posición a a un átomo de nitrógeno en el anillo; o donde en el caso particular donde R³ representa heteroarilo el cual es piridinilo, dicho piridinilo puede estar presente adicionalmente en forma del respectivo N-óxido; o su sal farmacéuticamente aceptable. Reivindicación 19: Un compuesto de la fórmula (2) donde R² y X son según lo definido para los compuestos de fórmula (1) de acuerdo con cualquiera de las reivindicaciones 1 a 11.
ARP140104303A 2013-11-19 2014-11-17 Compuestos tricíclicos de piperidina AR098436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2013060237 2013-11-19

Publications (1)

Publication Number Publication Date
AR098436A1 true AR098436A1 (es) 2016-05-26

Family

ID=51903926

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104303A AR098436A1 (es) 2013-11-19 2014-11-17 Compuestos tricíclicos de piperidina

Country Status (14)

Country Link
US (1) US9765092B2 (es)
EP (1) EP3071578B1 (es)
JP (1) JP6466937B2 (es)
KR (1) KR102390234B1 (es)
CN (1) CN105745214B (es)
AR (1) AR098436A1 (es)
AU (1) AU2014352008B2 (es)
CA (1) CA2926600A1 (es)
EA (1) EA029391B1 (es)
ES (1) ES2663124T3 (es)
MX (1) MX368635B (es)
PL (1) PL3071578T3 (es)
TW (1) TWI658043B (es)
WO (1) WO2015075023A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US10189839B2 (en) 2013-11-19 2019-01-29 Actelion Pharmaceuticals Ltd Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN106905261B (zh) * 2015-12-14 2020-10-30 杭州健昵福生物科技有限公司 1，3，4-硒二唑衍生物的合成方法
TW201818964A (zh) 2016-09-30 2018-06-01 瑞士商諾伊曼特醫療公司 使用色胺酸羥化酶抑制劑之方法
CN111004171A (zh) * 2019-12-18 2020-04-14 南开大学 3-氟吡啶-2-甲醇的一种新合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002105085A (ja) * 2000-09-28 2002-04-10 Yamanouchi Pharmaceut Co Ltd 新規イミダゾチアゾール誘導体
WO2002038153A1 (en) 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
KR100880133B1 (ko) * 2004-06-09 2009-01-23 에프. 호프만-라 로슈 아게 항바이러스성 화합물로서의 옥타히드로-피롤로[3,4-ｃ]유도체 및 그의 용도
RU2008120141A (ru) * 2005-11-30 2010-01-10 Ф. Хоффманн-Ля Рош Аг (Ch) 3-амино-2-арилпропилазаиндолы и их применения
CN101351451B (zh) 2005-12-29 2013-02-20 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
KR20100055464A (ko) * 2007-08-15 2010-05-26 액테리온 파마슈티칼 리미티드 오렉신 길항제로서의 1,2-디아미도-에틸렌 유도체
CN102264722B (zh) * 2008-12-23 2014-04-02 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮酰胺
WO2011068233A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2014195847A2 (en) 2013-06-03 2014-12-11 Actelion Pharmaceuticals Ltd Novel use of stable isotope labeled l-tryptophan

Also Published As

Publication number Publication date
EA201600394A1 (ru) 2016-10-31
CN105745214B (zh) 2019-02-19
CA2926600A1 (en) 2015-05-28
CN105745214A (zh) 2016-07-06
AU2014352008A1 (en) 2016-07-07
TW201605868A (zh) 2016-02-16
PL3071578T3 (pl) 2018-07-31
TWI658043B (zh) 2019-05-01
KR20160077216A (ko) 2016-07-01
EA029391B1 (ru) 2018-03-30
US9765092B2 (en) 2017-09-19
ES2663124T3 (es) 2018-04-11
AU2014352008B2 (en) 2018-08-16
US20160272655A1 (en) 2016-09-22
EP3071578B1 (en) 2018-01-10
WO2015075023A1 (en) 2015-05-28
JP6466937B2 (ja) 2019-02-06
EP3071578A1 (en) 2016-09-28
JP2016537376A (ja) 2016-12-01
MX368635B (es) 2019-10-09
KR102390234B1 (ko) 2022-04-22
MX2016006509A (es) 2016-08-04

Similar Documents

Publication Publication Date Title
AR098436A1 (es) Compuestos tricíclicos de piperidina
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR091424A1 (es) Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
AR103252A1 (es) Compuestos de quinazolina
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR108011A1 (es) Moduladores receptores de estrógenos
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR097755A1 (es) Derivados sustituidos de fenilalanina como moduladores del factor xia
AR090994A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR087984A1 (es) Derivados biciclicos de dihidroquinolina-2-ona
AR114828A1 (es) Compuestos de pteridinona y sus usos
AR097279A1 (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
AR087901A1 (es) Derivados dihidroquinolina-2-ona como inhibidores de la aldosterona sintasa y procedimiento para su obtencion
AR097571A1 (es) Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR091261A1 (es) Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa
AR097754A1 (es) Derivados sustituidos de fenilalanina
AR097756A1 (es) Derivados de fenilalanina sustituidos
AR093408A1 (es) Derivados de oxazolidin-2-ona-pirimidina

Legal Events

Date Code Title Description
FB Suspension of granting procedure